Contact
Please use this form to send email to PR contact of this press release:
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
TO:
Please use this form to send email to PR contact of this press release:
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
TO: